Clinical Evaluation |
---|
Somatostatin receptor expression |
Type of Imaging |
PET |
Grade of Recommendation |
C/D (optional) |
Level of Evidence |
well-designed Nuclear Medicine recommendations |
Effective Dose |
17.0-23.0 µSv/MBq |
Bibliographic Reference |
Bozkurt, M.F., Virgolini, I., Balogova, S., Beheshti, M., Rubello, D., Decristoforo, C., Ambrosini, V., Kjaer, A., Delgado-Bolton, R., Kunikowska, J.,...
read more
Bozkurt, M.F., Virgolini, I., Balogova, S., Beheshti, M., Rubello, D., Decristoforo, C., Ambrosini, V., Kjaer, A., Delgado-Bolton, R., Kunikowska, J., Oyen, W.J.G., Chiti, A., Giammarile, F., Sundin, A., Fanti, S. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur J Nucl Med Mol Imaging. 2017; https://doi.org/10.1007/s00259-017-3728-y
read less
|
Guide to Nuclear Medicine |
Read the corresponding chapter |